Delcath Systems Presents New Data on Liver Cancer Treatment at ESMO
Delcath Systems, Inc. has presented new data at the ESMO Breast Cancer Congress 2026 on the use of percutaneous hepatic perfusion with melphalan (M-PHP) for treating liver-dominant metastatic breast cancer. The retrospective analysis involved 15 patients and evaluated the feasibility, safety, and tumor response of the treatment. The study found that 60% of patients achieved a hepatic partial response, with a median overall survival of 6 months. The treatment was associated with significant adverse events, including bone marrow suppression and neutropenic-related infections, but these were typically resolved within a week. 
